A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
Vaccination is commonly used to control equine respiratory pathogens such as equine herpesvirus type 1 (EHV-1) and equine influenza virus (EIV). Here, we describe the generation and characterization of a recombinant EHV-1 modified live virus vaccine (MLV) based on a recent abortogenic EHV-1 strain, NY03. The immunogenicity and efficacy of the MLV was tested in horses in an EHV-1 vaccination/challenge experiment using the highly virulent neurovirulent EHV-1 strain OH03. Induction of a robust EHV-1-specific immune response was observed. Upon challenge infection, vaccinated horses were partially protected against disease as demonstrated by a significant reduction in clinical signs, nasal shedding and viremia levels. In addition, the NY03-based MLV was used to express the EIV H3 protein and immunogenicity was tested in horses. Expression of H3 was readily detected in NY03-H3-infected cells in vitro. Vaccination of horses resulted in the induction of a robust serological immune responses against two recent but genetically distinct EIV representatives, VA05 and NY-99, which were above the threshold predicted to be protective against development of clinical disease.
Van de Walle
Gerlinde R
GR
The Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
May
Maeva A
MA
Peters
Sarah T
ST
Metzger
Stephan M
SM
Rosas
Cristina T
CT
Osterrieder
Nikolaus
N
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005822:Genetic Vectors; D006566:Herpesviridae Infections / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary; D004861:Herpesvirus 1, Equid / Q000235:genetics / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000235:genetics / Q000276:immunology*; D006734:Horse Diseases / Q000276:immunology / Q000517:prevention & control*; D006736:Horses; D053123:Influenza A Virus, H3N8 Subtype / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology*; D009976:Orthomyxoviridae Infections / Q000517:prevention & control / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014766:Viremia / Q000517:prevention & control; D017201:Virus Shedding / Q000276:immunology
D000914:Antibodies, Viral; D022283:Herpesvirus Vaccines; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic